Paul J. DiMeglio Ph.D.
Tetra’s Mission Statement
Providing Safe and Effective Treatments,
Dispensed Exclusively through Physicians,
Adding Value to Their Practice, and
Successful Outcomes for Their Patients
We invented oil-soluble tolnaftate & products with tolnaftate in-solution
Tetra’s core technology is the process to make the drug tolnaftate soluble in jojoba oil – an invention of our founder, Paul J. DiMeglio Ph.D. (h.c). Tolnaftate was synthesized in the early 1950’s and was made an over the counter (“OTC”) drug by the U.S. Food and Drug Administration in 1965. In 1993 the final monograph for suspensions of tolnaftate was published. Until Dr. DiMeglio developed and patented his process, tolnaftate was insoluble in either oil or water. In all of the other medications available worldwide, whether in consumer pharmacies, retail outlets and on the internet, the tolnaftate is in suspension. At Tetra, all of our products have Dr. DiMeglio’s invention – soluble tolnaftate.
Soon after its formation, Tetra began marketing all of its products to the professional beauty industry and some of its products to independent pharmacies. Tetra also sold some of its products directly to the consumer. In 2006, Dr. DiMeglio was contacted by a podiatrist who had witnessed how quickly Formula 3®cleared his wife’s fungus. This doctor’s successful treatment of his patients was a revelation to Tetra. That doctor’s phone call, more than any market research and market experience from the past, was a breakthrough for Tetra. There was a need in medicine for a treatment that Formula 3® was uniquely qualified to satisfy. Tetra began marketing Formula 3®to physicians on July 16, 2006.
During the second quarter of 2008, Tetra changed its approach when addressing medical professionals. The strategy was founded on three key areas: 1) Tetra’s perfection of its manufacturing technology; 2) making Formula 3® a doctor only dispensed OTC; 3) and backing Formula 3® with the first unconditional, patient-direct, money-back guarantee offered in the pharmaceutical industry.
Although Formula 3® is manufactured as an OTC medication, Tetra’s strategy is to make it available exclusively through physician’s offices. On December 31, 2008, the last agreement with a national health and beauty distributor expired and none were renewed. Since January 1, 2009, Formula 3® has been and still is being dispensed primarily by doctors of podiatric medicine and dermatologic medicine.
Tetra’s Formula 3® guarantee is valid for US residents only. Limit of one refund per person, household or address. Duplicate claims will not be accepted. The Tetra Corporation reserves the right to rescind, revoke or amend this guarantee without further notice and at The Tetra Corporation’s sole discretion. The Tetra Corporation reserves the right to refuse any refund where fraud or illegal activity is suspected. Tetra’s guarantee does not apply to any online purchase. Only a purchase at the office of a licensed medical practitioner is guaranteed.